Corey S. Cutler, MD, MPH, FRCPC

Articles

HSCT Approaches to Retain GVL While Preventing GVHD

May 6th 2022

Expert perspectives on novel transplantation strategies to prevent or improve outcomes in graft-versus-host disease.

Novel Targeted Agents in GVHD: The FLIGHT and AGAVE-201 Trials

May 6th 2022

Brief insight on the FLIGHT and AGAVE-201 trials in chronic GVHD, which analyzed itacitinib, a JAK inhibitor, and axatilimab, a CSF1R inhibitor, respectively.

Chronic GVHD: Novel Treatment Approaches With Approved Agents

April 29th 2022

Considerations for novel treatment approaches with approved agents in combination or the frontline setting of chronic graft-vs-host disease.

Selecting Second-Line Therapy for Chronic GVHD

April 29th 2022

Shared insight on how best to select ibrutinib, belumosudil, or ruxolitinib for patients with steroid-refractory chronic graft-vs-host disease.

Chronic GVHD: Real-World Use of Ruxolitinib

April 22nd 2022

Closing out his summation of ruxolitinib in chronic GVHD, Yi-Bin Chen, MD, considers how real-world use compares with the REACH3 trial results.

REACH3 Trial: Approval of Ruxolitinib in Chronic GVHD

April 22nd 2022

Comprehensive insight on the design and results of REACH3, which analyzed ruxolitinib as second-line therapy for chronic graft-vs-host disease.

Mechanism of Action of Ruxolitinib

April 15th 2022

In the context of chronic graft-vs-host disease, expert Yi-Bin Chen, MD, provides an overview of ruxolitinib’s mechanism of action.

Belumosudil’s Approval and Use in Chronic Graft-Vs-Host Disease

April 15th 2022

Haris Ali, MD, shares insight on belumosudil, a ROCK2 inhibitor approved in the management of chronic graft-vs-host disease.

Ibrutinib’s Approval and Use in Chronic Graft-Versus-Host Disease

April 8th 2022

Corey Cutler, MD, MPH, FRCPC, breaks down the mechanism of action and FDA approval of ibrutinib, a BTK inhibitor, in chronic graft-versus-host disease.

Identifying and Managing Steroid-Refractory Chronic GVHD

April 8th 2022

Expert perspectives on optimal treatment strategies for patients who develop steroid-refractory chronic graft-versus-host disease.

Defining Steroid-Refractory and Steroid-Dependent GVHD

April 1st 2022

Yi-Bin Chen, MD outlines the definition of steroid-refractory vs steroid-dependent graft-vs-host disease.

Frontline Treatment Options for Chronic GVHD

April 1st 2022

A comprehensive breakdown of frontline treatment strategies for patients with newly diagnosed chronic graft-vs-host disease.

Dr. Cutler on the Examination of Itolizumab in aGVHD

March 30th 2022

Corey S. Cutler, MD, MPH, FRCPC, discusses the exploration of itolizumab in acute graft-versus-host disease.

Acute vs Chronic GVHD: Identification and Stratification

March 25th 2022

Insight on the identification of acute versus chronic graft-versus-host disease, including best diagnostic and risk stratification practices.

Background on Graft-vs-Host Disease: Risk Factors and Prevention

March 25th 2022

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft-versus-host disease, followed by insight on standard disease prevention practices.

The Evolving Treatment Landscape of Chronic GVHD

November 17th 2021

Closing out his discussion on chronic GVHD, Corey Cutler, MD, MPH, FRCPC, discusses belumosudil and how all 3 newly approved agents fit into the evolving treatment landscape.

REACH-3 Trial of Ruxolitinib in Steroid-Refractory Chronic GVHD

November 17th 2021

Expert insight on the study design and results of REACH-3, which tested ruxolitinib in patients with steroid-refractory chronic GVHD.

REACH-2 Trial of Ruxolitinib in Steroid-Refractory Acute GVHD

November 17th 2021

Corey Cutler, MD, MPH, FRCPC, reviews the study design and results of REACH-2, which tested ruxolitinib in patients with steroid-refractory acute GVHD.

An Overview of Treatment Options for Chronic GVHD

November 17th 2021

A comprehensive review of the treatment armamentarium for patients with chronic graft vs host disease.

An Overview of the Graft vs Host Disease Landscape

November 17th 2021

Corey Cutler, MD, MPH, FRCPC, provides an overview of graft vs host disease and some of the factors that may put patients at higher risk.